Activation of the phosphatidylinositol 3-kinase pathway plays important roles in reduction of cerebral infarction by cilnidipine

Journal of Neurochemistry

Volumn 135, Issue 1, 2015, Pages 186-193

  Son, Jeong Woo ^a   Choi, Hojin ^b   Yoo, Arum ^b   Park, Hyun Hee ^b   Kim, Young Seo ^b   Lee, Kyu Yong ^b   Lee, Young Joo ^b   Koh, Seong Ho ^a  

^a Hanyang University Guri Hospital   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

Author keywords

calcium channel blocker; phosphatidylinositol 3 kinase; stroke

Indexed keywords

CASPASE 3; CILNIDIPINE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; 1,4-DIHYDROPYRIDINE; DIHYDROPYRIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN SIZE; CONTROLLED STUDY; ENZYME ACTIVATION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; BRAIN; CEREBRAL INFARCTION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; CEREBRAL INFARCTION; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; HYPERTENSION; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84942505767     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13254     Document Type: Article

References (27)

1. Cantley L. C., (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
2. Cantrell D. A., (2001) Phosphoinositide 3-kinase signalling pathways. J. Cell Sci. 114, 1439-1445.
3. Fogelholm R., Erila T., Palomaki H., Murros K., and, Kaste M., (2000) Effect of nimodipine on final infarct volume after acute ischemic stroke. Cerebrovasc. Dis. 10, 189-193.
4. Frame S., Cohen P., and, Biondi R. M., (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327.
5. Gelmers H. J., Gorter K., de Weerdt C. J., and, Wiezer H. J., (1988) A controlled trial of nimodipine in acute ischemic stroke. N. Engl. J. Med. 318, 203-207.
6. Horn J., and, Limburg M., (2001) Calcium antagonists for ischemic stroke: a systematic review. Stroke 32, 570-576.
7. Hosono M., Iida H., Ikeda K., et al., (1992) In vitro and ex vivo Ca-antagonistic effect of 2-methoxyethyl(E)-3-phenyl-2-propen-1-yl(+/))-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate (FRC-8653), a new dihydropyridine derivative. J. Pharmacobiodyn. 15, 547-553.
8. Koh S. H., Park Y., Song C. W., et al., (2004) The effect of parp inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur. J. Neurosci. 20, 1461-1472.
9. Koh S. H., Chang D. I., Kim H. T., et al., (2005) Effect of 3-aminobenzamide, parp inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology 214, 131-139.
10. Koh S. H., Kim K. S., Choi M. R., et al., (2008a) Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res. 1229, 233-248.
11. Koh S. H., Noh M. Y., and, Kim S. H., (2008b) Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 1188, 254-262.
12. Koh S. H., Yoo A. R., Chang D. I., Hwang S. J., and, Kim S. H., (2008c) Inhibition of gsk-3 reduces infarct volume and improves neurobehavioral functions. Biochem. Biophys. Res. Commun. 371, 894-899.
13. Lee K. Y., Koh S. H., Noh M. Y., Kim S. H., and, Lee Y. J., (2008) Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity. Toxicology 243, 43-50.
14. Lee Y. J., Park K. H., Park H. H., et al., (2009) Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway. J. Neurochem. 111, 90-100.
15. Lohn M., Muzzulini U., Essin K., et al., (2002) Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C. J. Hypertens. 20, 885-893.
16. Martinez-Vila E., Guillen F., Villanueva J. A., et al., (1990) Placebocontrolled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke 21, 1023-1028.
17. Pap M., and, Cooper G. M., (2002) Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway. Mol. Cell. Biol. 22, 578-586.
18. Perez-Pinzon M. A., Yenari M. A., Sun G. H., Kunis D. M., and, Steinberg G. K., (1997) SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J. Neurol. Sci. 153, 25-31.
19. Pringle A. K., Benham C. D., Sim L., Kennedy J., Iannotti F., and, Sundstrom L. E., (1996) Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. Stroke 27, 2124-2130.
20. Sahota P., and, Savitz S. I., (2011) Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 8, 434-451.
21. Takahara A., Konda T., Enomoto A., and, Kondo N., (2004) Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model. Biol. Pharm. Bull. 27, 1388-1391.
22. Takeda K., Yamagishi R., Masumiya H., Tanaka H., and, Shigenobu K., (2004) Effect of cilnidipine on L- and T-type calcium currents in guinea pig ventricle and action potential in rabbit sinoatrial node. J. Pharmacol. Sci. 95, 398-401.
23. Takizawa S., Matsushima K., Fujita H., Nanri K., Ogawa S., and, Shinohara Y., (1995) A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 15, 611-618.
24. The American Nimodipine Study Group (1992) Clinical trial of nimodipine in acute ischemic stroke. The American Nimodipine Study Group. Stroke 23, 3-8.
25. Tominaga M., Ohya Y., Tsukashima A., et al., (1997) Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc. Drugs Ther. 11, 43-48.
26. Weiss J. H., Hartley D. M., Koh J., and, Choi D. W., (1990) The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. Science 247, 1474-1477.
27. Yoshimoto R., Dohmoto H., Yamada K., and, Goto A., (1991) Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4-dihydropyridine calcium antagonist cinaldipine (FRC-8653). Jpn. J. Pharmacol. 56, 225-229.